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Abstract
Gastrointestinal stromal tumors (GISTs) are characterized by alterations in genes involved in cell cycle regulation.
Although p16 (INK4A) have been extensively investigated in GISTs, there are still discrepancies regarding its prog-
nostic value. Therefore, we evaluated the clinical occurrence, diagnostic and prognostic value of p16 staining in
GIST. One hundred one patients (54 women and 47 men) with a mean age of 64.1 years (range, 17-94 years) were
surgically treated for a GIST within a 10-year period. Of these patients, 28 (28%) were affected by metastases
(mean follow-up, 4.5 years). In 36 patients (36%), GIST occurred coincidentally with other malignancies. Expres-
sion of c-kit was confirmed in 97 GIST patients (96%). In patients with high-risk GIST, the expression of p16 ex-
pression was highly predictive for poor prognosis, i.e., the development of recurrence or metastases (P = .006)
and poor survival (P = .004). In addition, the expression of p16 was highly predictive for reduction of the survival in
patients who were affected by metastases or recurrence (P = .041). The disease-specific and disease-free 1-, 3-,
and 5-year survival rate was 96%, 90%, and 85% and 81%, 77%, and 72%, respectively. Primary tumor state,
tumor size, and high-risk classification were confirmed as relevant predictors for unfavorable prognosis in GIST
(P < .001). Our results indicate that in high-risk GIST and in patients with recurrence or metastases, the expression
of p16 is highly predictive for poor outcome. Thus, in addition to high-risk classification, p16 expression might be
an indicator for “very high risk GIST.”
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Introduction
Gastrointestinal stromal tumors (GISTs) constitute the largest group
of mesenchymal tumors with an overall incidence of 1 to 2 per
100,000 per year [1] and are characterized by the expression of
CD117 (c-kit) [2–4]. Gain-of-function mutations of the c-kit gene
resulting in consecutive changes in mitotic rate, proliferation, and
differentiation are considered to be the major step in the pathogen-
esis of GIST [2,4–8]. Recently, a general risk classification was estab-
lished (Table 1) [3,6,7]. However, regardless of several predicting
parameters, among them tumor size and mitotic rate, the clinical be-
havior of GISTmarkedly varies [6]. Therefore, analysis of additional
factors allowing a more detailed prognosis for the individual patient
is still a pertinent issue.
Detailed characterization of several cell cycle regulators, particu-
larly p16, revealed that they have a great impact on the pathogenesis
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of GIST. Loss of p16 has been reported to predict poor clinical out-
come in a variety of several human tumors [9–14]. The prognostic sig-
nificance of p16 gene alterations in GIST is still under debate [14–21].
Loss of p16 protein expression in GIST is described as a significant
predictive value in some—but not all—studies. In contrast, an ad-
verse effect of p16 protein expression on prognosis was recently de-
scribed [22]. High-risk classification is a significant predictor of the
probability of developing metastases or recurrence [3,7]. However,
the subgroup of high-risk GIST is very heterogeneous. Unfortu-
nately, at present, no significant predictors exist which divide high-
risk GIST or which assess the prognosis of patients with GIST who
experienced tumor recurrence or metastases.
In this study, we evaluated the clinicopathologic features, diagnos-
tic appearance, and clinical outcome of patients with GISTs. Atten-
tion was focused on primary tumor state, on risk classification, and
on estimation of the clinical outcome. Due to the conflicting data
surrounding the prognostic value of p16 expression in GIST, the im-
munostaining pattern of p16 was additionally analyzed. Particular at-
tention was directed to patients with high-risk GIST. An individual
subgroup was created to analyze the prognostic value of p16 expres-
sion in this cohort.
Materials and Methods
Patients
Extending for 10 years, 101GIST patients (54 women and 47men)
with a mean age of 64.1 years (range, 17-94 years) underwent surgi-
cal resection through laparotomy for a GIST in our department. After
obtaining informed consent, chart review was carried out focusing on
the following parameters: initial clinical symptoms, pathologic fea-
tures, and clinical follow-up.
Clinical data were retrospectively reviewed based on the hospital
records including medical history and on results from the contribut-
ing radiologists and pathologists. Medical history and radiographic
data were collected if available in medical records. All 101 tumors
were defined as GISTs based on the combination of histologic eval-
uation (highly cellular spindle/epithelioid/mixed cell tumors) and
CD117 (c-kit) or—if negative—platelet-derived growth factor recep-
tor alpha (PDGFR-α) positivity followed by prospective assessment
of the clinical outcome.
Histologic Evaluation
Original hematoxylin and eosin–stained sections were reviewed in
each case. Mitoses were counted from 50 consecutive high-power
fields (HPFs) from the most cellular and mitotically active areas (area
of an individual field 0.2 mm2). In all cases, the feature of cell type
was recorded (spindle vs epithelioid or mixed cell–type). For the pur-
pose of clinicopathologic comparison, GISTs were classified accord-
ing to Fletcher et al. [3] (see also Table 1) and additionally divided in
two groups: “Non–high-risk” including all patients classified as “Very
low,” “Low,” or “Intermediate,” respectively and “High-risk.” In one
patient with neoadjuvant Gleevec therapy, mitotic count was done
on the initial cutting needle biopsy.
Immunohistochemical staining for CD117, PDGFR-α, and p16
was performed using the alkaline-phosphatase method in a Dako
AutoStainer (Dako, Denmark). Representative paraffin-embedded
tissue blocks were cut into 3-μm sections. After deparaffinization and
antigen demasking through microwave heating (20 minutes, citrate
buffer pH 6), the primary antibodies (p16INK4, 1:400; ZYTOMED
Systems GmbH, Berlin, Germany), CD117 (c-kit polyclonal anti-
bodies, at 1:200; Dako), and PDGFR-α (polyclonal antibodies, at
1:100; Dianova, Hamburg, Germany) were incubated on the slices
followed by incubation with the alkaline phosphatase–conjugated
streptavidin and the chromogenic substrate neofuchsin (Dako REAL
Detection System). Counterstaining was done with hematoxylin.
According to Schneider-Stock et al. [14], p16 immunohistochem-
ical staining was evaluated by estimating 10 HPFs. Nuclei of tumor
cells with or without cytoplasmatic staining were counted according
to a 4-point semiquantitative scale [no staining, 0-10% (0); weak,
11-20% (1); moderate, 21-50% (2); strong, >50% (3)]. A cutoff
at 20% positivity in at least 10 HPF was used for prognostic analysis.
Nontumorous stromal cells showing nuclear reactivity served as an
internal control. In addition to the evaluation protocol of Schneider-
Stock et al. [14], we also analyzed cutoff values at 10% and 50% and
compared these results.
Statistical Analysis
For statistical analysis, the two-sided χ2 test or Fisher exact test in
cross tables was used to demonstrate the relation between different
qualitative outcome parameters, such as GIST-related death (yes/no),
the occurrence of tumor recurrence or metastases (yes/no), and sev-
eral independent variables with particular focus on p16 staining. For
the analysis of the disease-specific survival (DSS) and disease-free sur-
vival (DFS), the total survival curves (Kaplan-Meier) were compared
using the log-rank test. Deaths from unrelated causes were censored
[14]. The study followed an explorative data analysis. Therefore,
the P values were not adjusted for multiple testing and no single
main outcome parameter was defined, all parameters were of equally
interest. A P value of <.05 was considered statistically relevant.
Calculations were performed using WinSTAT (R. Fitch Software,
Germany), SAS/STAT (SAS Institute Inc., Cary, NC) and SPSS
(SPSS Inc., Chicago, IL).
Results
One hundred one patients with a mean age of 64.1 years (SD,
13.4) and a male/female ratio of 54:47 (54% were men, 46% were
women) underwent surgical resection for a GIST through laparot-
omy. Clinical manifestations, diagnostic imaging, pathologic find-
ings, treatment options, and clinical outcome were evaluated.
Clinical Presentation
Clinical symptoms predominantly manifested as abdominal pain
36% (36/101), GI bleeding 28% (28/101), and unspecific symptoms
such as fatigue and weight loss. However, 31 patients (31%) were
asymptomatic. Tumor size was ranging from 0.4 to 20.0 cm (median,
5.5 cm), and two patients showed diffuse peritoneal tumor spread.
In 15 patients (15%), the GIST was incidentally detected during
Table 1. Risk of Malignancy According to Fletcher et al.
Risk Size (cm) Mitotic Activity per 50 HPFs
Very low risk <2 <5
Low risk 2-5 <5
Intermediate risk <5 6-10
5-10 <5
High risk >5 >5
>10 Any rate
Any size >10
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major surgical procedures. In total, 44 GIST patients (44%) showed
additional tumors (benign or malign), whereas in 36 patients (36%),
the GIST occurred in coincidence with a malignant tumor (iso- or
metachronic). Five patients (5%) had neurofibromatosis type 1. These
results are also shown in Table 2.
Primary Tumor Site and Staging
The GISTs were predominantly located in the stomach (n = 60,
61%) and small intestine (n = 33, 33%; Table 2). Of the 101 pa-
tients, 14 (14%) had primary metastatic disease, 87 (86%) had only
a locally limited primary growth. In total, 28 (28%) patients were
affected by metastases or tumor recurrence at any time.
Surgical Treatment
Unless the local growth of the GIST itself or other additional ma-
lignancies required multivisceral resection, a local resection either of
the stomach (wedge resection) or small intestine (segment resection)
was performed. Dependent on the primary tumor site and the extent
of tumor growth, complete resection could be achieved in 86% of
the patients: in 88 patients, final resection state was R2 in 8 (9%),
R1 in 4 (5%), and R0 in 76 (86%).
Metastases as well as Recurrence in GIST and
Medical Treatment
In 101 patients, 14 (14%) had primary metastatic disease. A little
more than one quarter of the patients (28/101, 28%) experienced
recurrences or metastases within a median time of 1.93 years (range,
0.08-9.59 years; mean, 2.94 years). Thirteen patients were treated
with imatinib (200-800 mg/day) in addition to surgery. Of these
13 patients, 6 (46%) achieved stable disease, 4 (31%) attained a par-
tial remission, and 3 (23%) experienced tumor progression. Once, a
neoadjuvant approach was realized within 15 weeks of preoperative
application of imatinib (400 mg/day), which was continued after
surgery. Imatinib did not lead to a complete remission in any of
our patients.
Histopathologic and Pathoanatomic Analysis
Histomorphology of the GISTs was predominantly spindle cell–
like (87/101, 86%). Of 101 GISTs, 2 (2%) were epithelioid-like
and 12 tumors (12%) exhibited a mixed pattern of growth. Mitotic
activity varied from apparently absent with no detectable mitotic
figures in 50 HPFs to high (up to 89 mitotic figures/50 HPFs). Ac-
cording to Fletcher et al. [3] and Miettinen et al. [7], the risk of ma-
lignancy was classified as listed in Table 2. Tumor size ranged from
0.4 to 20 cm (median, 5.5 cm).
Immunohistochemical staining of the specimens (see also Table 2)
showed c-Kit expression in 97% (97/101) of the tumors. CD34
expression was analyzed in 78 cases: 66 (85%) expressed CD34,
whereby in 3 cases, CD34 was only detected at low levels in a minor-
ity of tumor cells. By using 10%, 20%, or 50% positive cells as cut-
off value, the p16 expression was positive in 43%, 40%, or 16% and
negative in 57%, 60%, or 84% of all analyzed tumors (95/101).
Outcome
Clinical follow-up of all surviving patients was carried out after a
median interval of 4.13 years (range, 0.6-19 years; mean, 49.6 months;
range, 7.2-228 months). Seventy-one patients (71% overall survival
rate) are still alive, whereas 30 patients died (30% overall mortality
rate), of which 14 (47%) were GIST-related deaths. The 1-, 3-, and
5-year GIST-related survival probability was 96%, 90%, and 85%
(DSS) respectively. The overall recurrence rate was 28%. The 1-, 3-,
and 5-year DFS probability counts for 81%, 77%, and 72% (DFS),
respectively, are shown in Table 3.
Dependency of Parameters
P values regarding the dependency of different parameters are
listed in Table 4. The evaluations of survival predicting parameters
are limited due to the small number of GIST-related deaths (14/101,
14%). However, tumor size and mitotic rate showed a statistically
significant relation with the occurrence of metastases or recurrence
as well as with the DFS rate and could be considered as clinically rel-
evant. Also, risk classification (Figure 1) and the primary tumor state
showed a relation with the occurrence of GIST-related death (yes/no),
GIST-related survival rate, the occurrence of metastases or tumor re-
currence (yes/no), and with the DFS.
Table 2. Clinicopathologic Features.
Initial symptoms (multiple mentions possible) n % of 101
No clinical symptoms 31 31%
Pain 36 36%
GI bleeding 28 28%
Anemia 6 6%
Others 25 25%
Localization of primary tumor n % of 99
Stomach 60 61%
Small bowel 33 33%
Jejunum 10 10%
Ileum 18 18%
Duodenum 5 5%
Colon 1 1%
Esophagus 2 2%
Others (EGIST, etc.) 3 3%
Histomorphology n % of 101
Spindle cell–like 87 87%
Epithelioid 2 2%
Mixed pattern 12 11%
Risk of Malignancy (Fletcher et al.) n (% of 95) Gaster/Small
Bowel/Other (n)
High risk 37 (39%) 20/12/3
Intermediate risk 20 (21%) 14/5/1
Low risk 22 (23%) 13/9/0
Very low risk 16 (17%) 9/5/2
Immunohistochemistry Positive, n (%) Negative, n (%) Total, N
c-kit 97 (97%) 3 (3%) 100
p16 (10%) 41 (43%) 54 (57%) 95
P16 (20%) 38 (40%) 57 (60%) 95
P16 (50%) 15 (16%) 80 (84%) 95
CD34 66 (85%) 12 (15%) 78
Aktin 14 (21%) 54 (79%) 68
Desmin 4 (8%) 44 (92%) 48
Vimentin 32 (100%) 0 (0%) 32
NSE 7 (58%) 5 (42%) 12
S100 1 (2%) 56 (98%) 57
EGIST indicates extra gastrointestinal stromal tumor; NSE, neuron-specific enolase.
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In total, staining for p16 (only by taking a cutoff > 50%) was as-
sociated with poor outcome but statistically did not reach a level of
relevance (P = .080, log-rank test; DSS).
Therefore, in patients with high-risk GIST, the p16 expression was
highly predictive for the reduction of DSS and DFS. Depending on
the cutoff value, the P values in this subgroup were as follows: >10%,
P = .118 (DSS) and P = .058 (DFS); >20%, P = .022 (DSS) and P =
.006 (DFS); >50%, P = .004 (DSS) and P = .012 (DFS; Tables 5 and
6; Figures 2 and 3). Within the subgroup of patients who were af-
fected by metastases or recurrence at any time, only the expression of
p16 showed a statistically relevant relation with reduction of the sur-
vival (P = .041, log-rank test; cutoff, 50%).
The most significant prognostic value was finally found by out-
come analysis comparing the combination of immunohistochemical
p16-positive high-risk GISTwith the remaining patients of the whole
study population (all non–high-risk GIST regardless of p16 status
and p16-negative high-risk GIST) as shown in Figures 4 and 5
and Table 4. The combination of p16 positivity and high-risk GIST
showed the most highly predictive P values, independent of the cut-
off values (DSS and DFS: P < .001, log-rank test; any cutoff value).
In multivariate analyses, no statistically relevant relating factors
could be detected in addition.
Discussion
The aim of this study was to evaluate the prognostic value of p16
expression in GIST. Therefore, in 101 patients with GIST, the p16
immunostaining pattern of tumors was evaluated and statistically
analyzed with regard to the dependency with clinicopathologic fea-
tures, diagnostic appearance, and clinical outcome. Although high-
risk classification is highly predictive in determining the probability
of developing metastases or recurrence [3], this subgroup still re-
mains heterogeneous. There exist no reliable parameters to further
Table 4. P values.
Independent Variables Tumor-Related Death DSS DFS Metastases/Recurrence Count (n)
Fisher Exact/χ2 Test, P Log-Rank Test, P Log-Rank Test, P Fisher Exact/χ2 Test, P
Sex .779 .657 .724 .665 101
Localization (stomach vs small bowel) 1.000 .935 .395 .709 99
Tumor size (≥5 cm vs <5 cm) .005 .008 <.001 <.001 94
Mitotic rate (≥5/50 HPF vs <5/50 HPF) .005 .007 <.001 <.001 92
Fletcher (high vs non-high) <.001 <.001 <.001 <.001 95
Primary tumor state (unifocal vs not local) <.001 <.001 <.001 — 101
CD34 (positive vs negative) 1.000 .670 .590 1.000 88
Aktin (positive vs negative) 1.000 .611 .236 .319 68
Desmin (positive vs negative) 1.000 .935 .601 1.000 48
p16 (positive vs negative, whole population)
Cutoff > 10% .980 .818 .897 .764 95
Cutoff > 20% .813 .596 .745 .926 95
Cutoff > 50% .226 .080 .207 .279 95
p16 (p16-positive high-risk GIST vs the rest)
Cutoff > 10% <.001 <.001 <.001 <.001 95
Cutoff > 20% <.001 <.001 <.001 <.001 95
Cutoff > 50% <.001 <.001 <.001 <.001 95
P < .05 were considered significant (bold face emphases).
Table 3. Results of the Survival Analysis.
1-Year Probability (%) 3-Year Probability (%) 5-Year Probability (%)
Overall 91.9 80.8 69.5
DSS 95.9 89.7 84.9
DFS 80.8 77.1 72.2
1-Year DSS (%) 3-Year DSS (%) 5-Year DSS (%) 1-Year DFS (%) 3-Year DFS (%) 5-Year DFS (%)
Prim-loc. 100 98.6 93.0 94.0 89.6 83.9
Prim-met. 70.1 35.1 35.1 — — —
Met: any time 85.4 65.1 50.7 — — —
R0 resection 97.3 95.7 89.1 88.0 84.8 82.8
R1/2 resection 83.3 46.3 — 33.3 25.0 —
p16 (10%) Positive 94.7 84.8 80.5 79.9 79.9 72.0
Negative 96.3 92.1 86.8 79.3 75.1 72.5
p16 (20%) Positive 94.4 83.8 79.1 78.9 78.9 70.1
Negative 96.4 92.4 87.4 80.1 76.0 73.5
p16 (50%) Positive 92.3 73.8 63.3 66.0 66.0 56.6
Negative 96.2 91.7 87.9 81.1 79.1 74.8
Risk of malignancy Very low 100 100 100 100 100 100
Low 100 94.1 94.1 95.5 95.5 95.5
Intermediate 100 100 100 100 100 100
High 88.7 75.5 64.5 50.2 43.9 37.7
Non-high 100.0 97.7 97.7 98.2 98.2 98.2
Met indicates metastases or recurrence at any time; Prim-loc, primarily localized; Prim-met, primarily metastases.
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specify the individual risk of developing tumor recurrence, metas-
tases, or GIST-related death. Furthermore, there are no significant
predictors to assess the prognosis of GIST patients with tumor recur-
rence or metastases. Therefore, high-risk GIST and patients who
were affected by metastases or tumor recurrence were specifically
analyzed in individual subgroups to evaluate the prognostic value
of p16 expression in these cohorts.
Of the 101 patients, GIST in 15 (15%) was accidentally detected
during major surgery. Furthermore, in clinical presentation, the lead-
ing symptoms were abdominal pain (36%) and GI bleeding (28%),
which are higher in comparison to other published data where bowel
obstruction (15%) and perforation (10%) are the major problems
[9,23–26]. These were only found in a few cases in our study. Sim-
ilarly, the distribution of the risk classification differs. In contrast to
Orosz et al. [27], who reported an 80% rate of high-risk tumors
within a study of 136 patients, we found a rate of only 39% (Table 2).
One explanation for this discrepancy might be that the diagnosis was
made at an earlier stage in our patients. As suggested previously, such
data could vary (reviewed in Rubin et al. [28]), and this highlights
the limited comparability of different populations.
Interestingly, in comparison to other studies [5,23–26,29–39], we
report the highest coincidence rate concerning additional malignan-
cies in GIST (36/101, 36%). Since 2000, the coincidence rate of ma-
lignancies in GIST is described in several studies ranging between
4.5% and 26.8% while the study size encompasses from 18 to
747 GIST patients [5,23–26,29–39]. This leads to a mean rate of
10% for additional malignancies in GIST patients. Whether there
might be a biologic interaction related to the coincidence of GIST
and additional neoplasia remains to be further investigated.
In our study, approximately one quarter of the GIST patients (28/
101, 28%) were affected by recurrence or metastases and half of these
(14%) had primary metastatic GIST disease. This is low compared to
a 50% rate published by two other groups [6,35]. This difference
might be explained by the selection of patients due to the different
character of the medical or surgical center. Nevertheless, our results
are supported by the findings of three studies reporting a 10% to
25% rate of patients with metastatic disease [36,40,41].
Of course, the outcome of patients after R1/R2 resection was worse
in comparison to R0 resection. These results are in accordance with
population-based studies reporting a median survival of 68 months
for complete resection, 51months for partial resection, and 10months
for no resection each with P ≤ .001. Outcomes in patients with
Figure 1. Disease-specific survival of the groups “High-risk” and “Non–high-risk” (Very Low, Low, and Intermediate) modified according
to Fletcher et al. (whole population).
Table 5. Results of the Log-Rank Tests Concerning the Subgroups of High-Risk GISTs and Pa-
tients with Recurrence or Metastasis.
p16 High-Risk (n = 37) Tumor Recurrence
or Metastases
DSS DFS DSS DFS
Cutoff > 10% P = .118 P = .058 P = .325 P = .586
Cutoff > 20% P = .022 P = .006 P = .325 P = .586
Cutoff > 50% P = .004 P = .012 P = .041 P = .239
Table 6. Disease-Specific and -Free Survival in High-Risk GIST.
1-Year
Probability (%)
3-Year
Probability (%)
5-Year
Probability (%)
Overall survival 91.9 80.8 69.5
DSS 95.9 89.7 84.9
DFS 80.8 77.1 72.2
High-Risk Patients (n = 37) 1-Year
DSS/DFS (%)
3-Year
DSS/DFS (%)
5-Year
DSS/DFS (%)
p16-positive
Cutoff > 10% 77.8/30.0 46.7/30.0 31.1/20.0
Cutoff > 20% 75.0/22.2 37.5/22.2 18.8/11.1
Cutoff > 50% 80.0/16.7 26.7/16.7 n.a./n.a.
p16-negative
Cutoff > 10% 92.6/57.8 84.2/48.9 74.4/44.5
Cutoff > 20% 92.9/59.4 84.8/50.9 75.5/46.7
Cutoff > 50% 90.1/56.9 82.6/49.3 74.0/45.5
n.a. indicates not available.
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completely resected tumors were found to be equivalent regardless of
whether they had wedge or total organ removal [23,42–44].
Obviously, concerning medical treatment, the number of only
13 patients who were treated with imatinib in our series does not
permit statistical conclusions. In general, response rates of 50% to
80% are reported after treatment with imatinib, whereas partial re-
mission in 40% to 50% of these patients is seen, and in one third, a
stable state might be achievable [5,6,40,43,44]. This is in accordance
with our data.
The 1-, 3-, and 5-year GIST-related survival probability of our pa-
tients is 96%, 90%, and 85% (DSS), respectively. Whereas the over-
all recurrence rate is 28%, the 1-, 3-, and 5-year DFS probability
counts for 81%, 77%, and 72%, respectively (Table 3). Taken to-
gether, the GIST survival rates of our patients seem to be rather high
in comparison to other published data [6,32,41,44,45].
Our immunohistochemical analysis revealed a profound expres-
sion of c-Kit in 97% (97/101) and of CD34 in 85% (66/78) of
the tumors. These results (Table 2) are in accordance with those of
previously published studies [3,27,46]. With regards to the whole
population of our study, the expression of p16 in GIST tends to re-
sult in predicting poor outcome, but a statistically relevant level is not
reached (P = .08, log-rank test – DSS; cutoff, 50%). Whereas in pa-
tients with high-risk GIST, the p16 expression was highly predictive
for the reduction of DFS and DSS (P = .012 and P = .004; cutoff,
50%). Depending on the cutoff value, the P values are listed in
Table 5. In addition, in our study, the expression of p16 is the only
Figure 2. Disease-specific survival of the groups p16-positive and p16-negative (cutoff > 20%, subgroup of High-risk according to
Fletcher et al.).
Figure 3. Disease-specific survival of the groups p16-positive and p16-negative (cutoff > 50%, subgroup of High-risk according to
Fletcher et al.).
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statistically relevant, thus highly predictive parameter regarding the
reduction of the DSS of GIST patients who were affected by metas-
tases or recurrence (P = .041; Table 5). Therefore, p16 staining might
be used as predictor.
However, at present, it is still difficult to estimate the predict-
ing value of p16 in GIST, although this issue has been addressed
in several publications [14–22,47]. Because different methods, dif-
ferent cutoff values, different follow-up durations, and different
searching variables were used, the comparability of these data is lim-
ited. Most studies describe statistically relevant relations/associations
only with malignant risk classification [14–22,47] and not with the
GIST-related prognosis itself. Beside the here-presented data, the
results of only three additional studies [14,21,22] indicate a predic-
tive value of p16 expression in GIST, if P < .05 is considered statis-
tically significant.
In contrast to the data presented in our study, the loss of p16
was described twice as significantly predictive for poor outcome in
GIST (P < .02, n = 39 and P = .012, n = 159; cutoff, 20%) [14,21].
However, the according duration of follow-up was only 34 [21]
or 45 months [14], and the average center size was less than 39 pa-
tients in these studies, whereas in our single-center population, the
mean follow-up duration was 54 months (range, 3-229 months)
Figure 4. Disease-specific survival of the groups 1 and 2 (group 1: High-risk GISTs, p16-positive (cutoff > 20%); group 2: High-risk
GISTs, p16-negative and Non–high-risk GISTs regardless of p16 status).
Figure 5. Disease-specific survival of the groups 1 and 2 (group 1: High-risk GISTs, p16-positive (cutoff > 50%); group 2: High-risk
GISTs, p16-negative and Non–high-risk GISTs regardless of p16 status).
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and, within the subgroup of the surviving patients, even 61 months
(range, 7-229 months), thus at least 9 months longer. This emphasizes
the role of a sufficient follow-up duration. Certainly, only additional
long-term follow-up, within a further couple of years, may clarify the
relevance of the p16 expression in GIST.
The results of a third study are in accordance with our data. Steigen
et al. [22] also found a positive relation between p16 staining and
poor prognosis in GIST (n = 434, P = .013). Unfortunately, the me-
dian follow-up duration is not documented in their article [22],
and their data were acquired out of 20 departments of pathology
in Norway (average center size, ∼22 patients per center). Thus, our
study represents the largest single-center evaluation of p16 immu-
nostaining in GIST by including 101 patients with the longest
mean follow-up time, counting 54 months.
However, which pathophysiological role p16 might play in the on-
cogenesis of GIST remains to be further investigated. It might be
even different at certain stages of tumorigenesis. Actually, the loss
of p16 expression is biologically contributed to malignancy. How-
ever, if other oncogenic changes such as loss of RB or TP53 and
aberrant activation of cyclin D by gene amplification or by activating
mutations of the receptor tyrosine kinase ras-raf-ERK lead to highly
increased proliferation, the expression of p16 might also be a com-
pensatory reaction on oncogenic escalation of other origin. Indeed,
it is known that in cervical carcinomas the expression of p16 con-
tributes to malignancy [48,49] and in breast cancer even to poor out-
come [50]. Just recently, also in GIST the relation between p16
expression and the mitotic rate was confirmed [22].
The prognostic value of p16 in our study was also characterized
applying the more recently published Hornick and Fletcher classifi-
cation [51], which is based on the Miettinen and Lasota classification
[52]. Interestingly, the prognostic value of p16 in our study appeared
even more significant when using the Hornick and Fletcher clas-
sification (data not shown). In patients with high-risk GIST, the
p16 expression was highly predictive for the reduction of DSS and
DFS by using the Hornick and Fletcher classification (range, P <
.002 to P < .056). However, to the best of our knowledge, the risk
classification of Fletcher is still the accepted one, which was discussed
by the World Health Organization Consensus Conference in 2001.
As long as the risk classification of Hornick and Fletcher [51] is not
accepted within the context of the international, interdisciplinary
consensus conferences, we prefer to accord to the well-established
Fletcher consensus classification.
The conclusion of our study can be summarized as follows: the
major clinical symptoms in GIST are abdominal pain and GI bleed-
ing. To the best of our knowledge, we report the highest coincidence
of additional malignancies with GIST (36%). Primary tumor state
high-risk classification and the combination, “p16-positive high-risk
GIST,” are the statistically most relevant predictors for poor prog-
nosis. In high-risk GIST, the expression of p16 is highly predictive
for the reduction of the DFS and DSS. In patients with recurrence
or metastases, the expression of p16 seems to be the only clinical rel-
evant predictor. Therefore, p16 staining allows to differentiate high-
risk from “very high-risk” GIST and might be used as predictor.
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